ArticlePLoS computational biology2026
Integrating zero-inflation correction and transcriptional kinetics for single-cell transcriptomic analysis.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell transcriptomic data exhibit pervasive zero inflation, while traditional models either neglect this issue or fail to capture transcriptional burst-driven bimodality, hindering accurate gene regulatory studies. This study developed a zero-inflated telegraph model that integrates technical zero correction with the stochastic gene state-switching dynamics of the classical telegraph model. Systematic validation was conducted using synthetic data, human scRNA-seq data from lupus and breast cancer patients, and mouse embryonic stem cell scRNA-seq data. The model showed superior performance: it accurately fits mRNA distributions (including bimodal patterns), reliably estimates effective transcriptional burst parameters while preventing overfitting, thus enables correction of traditional models' regulatory inference bias. It also outperforms conventional approaches in detecting differentially expressed genes, with notable advantages in small samples, and identifies unique disease-related genes (e.g., LDLR, GZMB for lupus, FAIM2, VDR for breast cancer). This biologically interpretable and robust tool advances single-cell transcriptomic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.